Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature.

Détails

Ressource 1Télécharger: 37250819_BIB_8E786969EDB9.pdf (1284.14 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_8E786969EDB9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature.
Périodique
SAGE open medical case reports
Auteur⸱e⸱s
Liapi A., Atat C., Dunet V., Sarivalasis A.
ISSN
2050-313X (Print)
ISSN-L
2050-313X
Statut éditorial
Publié
Date de publication
2023
Peer-reviewed
Oui
Volume
11
Pages
2050313X231176401
Langue
anglais
Notes
Publication types: Case Reports
Publication Status: epublish
Résumé
Posterior reversible encephalopathy syndrome is a rare neurological disorder, the diagnosis of which is based on the combination of clinical and radiological findings. It can be associated with many patient-related conditions such as autoimmune disorders or can be provoked by toxins or medication. We report the case of a 70-year-old patient, known for International Federation of Gynecology and Obstetrics stage IVB, high-grade serous ovarian carcinoma, who was diagnosed with a posterior reversible encephalopathy syndrome while on bevacizumab and olaparib maintenance treatment.
Mots-clé
Posterior reversible encephalopathy syndrome (PRES), bevacizumab, olaparib, ovarian cancer
Pubmed
Web of science
Open Access
Oui
Création de la notice
05/06/2023 9:13
Dernière modification de la notice
25/01/2024 8:40
Données d'usage